# A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2

> **NCT01480323** · PHASE2 · COMPLETED · sponsor: **University Hospital Tuebingen** · enrollment: 15 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Interleukin-2
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT01480323
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2014-09
- **Final completion:** 2015-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2015-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01480323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01480323, "A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01480323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*